Dupixent® (dupilumab) Late-breaking Phase 3 Data at the

Nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo...

Related Keywords

Miami , Florida , United States , Tarrytown , Japan , Paris , France General , France , University Of Miami , Gil Yosipovitch , Georged Yancopoulos , Regeneron Velocimmune , European Academy Of Dermatology , Prnewswire Regeneron Pharmaceuticals Inc , Regeneron Genetics Center , European Commission , Drug Administration , Dupilumab Development Program , Regeneron Velocimmune Technology , Nasdaq , Miami Itch Center , European Union , Priority Review , European Academy , Miller School , Worst Itch Numeric Rating Scale , Global Assessment , Chief Scientific Officer George , Prescribing Information ,